Chronic myeloproliferative disorders

Childhood Leukemias, Second Edition

Volumn , Issue , 2006, Pages 571-598

  Niemeyer, Charlotte M ^a   Locatelli, Franco ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548121797     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511471001.023     Document Type: Chapter

References (308)

1. Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood, 1951; 6: 372-5.
2. Thiele, J., Pierre, R., Imbert, M., Vardiman, J. W., & Flandrin, G. Chronic idiopathic myelofibrosis. In E. S. Jaffe, N. L. Harris, H. Stein & J. W. Vardiman, eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoieticand Lymphoid Tissues (Lyon, France: IARC, 2001), pp. 35-8.
3. Vardiman, J. W. Myelodysplastic/myeloproliferative diseases. In E. S. Jaffe, N. L., Harris, H., Stein, J. W., & Vardiman, eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (Lyon, France: IARC, 2001), pp. 47-59.
4. Hasle, H., Kerndrup, G., &Jacobsen, B.B. Childhoodmyelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia, 1995; 9: 1569-72.
5. Hasle, H., Wadsworth, L.D., Massing, B. G., et al. A populationbased study of childhoodmyelodysplastic syndromein British Columbia, Canada. Br J Haematol, 1999; 106: 1027-32.
6. Solmitz, W. Ein Fall von myeloischer Leukämie im ersten Kindesalter. Zeitschr f Kinderh, 1924; 38: 146-58.
7. Cooke, J. V. Chronic myelogenous leukemia in children. J Pediatr, 1953; 42: 537-50.
8. Bernard, J., Seligmann, M., & Acar, J. La leucémie myeloide chronique de l_enfant. Étude de vingt observations. Arch Fr Pediatr, 1962; 19: 881-94.
9. Weisgerber, D. J., Schaison, G., & Seligmann, M. Les leucémies myélomonocytaires du petit enfant. Bull Cancer, 1969; 56: 351-64.
10. Weisgerber, C., Schaison, G., Chavelet, F., et al. Les leucémies myelo-monocytaires de l_enfant. Étude de 28 observations. Arch Fr Pediatr, 1972; 29: 11-30.
11. Schaison, G., Weisgerber, C., Seligmann, M., et al. Les leucémies myelo-monocytaires avec xanthomes. Nouv Rev Fr Hematol, 1970; 10: 284-8.
12. Castro-Malaspina, H., Schaison, G., Passe, S., et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer, 1984; 54: 675-86.
13. Reisman, L. E. & Trujillo, J. M. Chronic granulocytic leukemia of childhood. J Pediatr, 1963; 62: 710-23.
14. Hardisty, R. M., Speed, D. E., & Morwenna, T. Granulocytic leukemia in childhood. Br J Haematol, 1964; 10: 551-66.
15. Freedman, M. H., Estrov, Z., & Chan, H. S. Juvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol, 1988; 10: 261-7.
16. Beaven, G. H., Steven, B. L., Dance, N., et al. Occurrence of haemoglobin H in leukaemia. Nature, 1963; 199: 1297-8.
17. Weatherall, D. J., Edward, J. A., & Donohoe, W. T. Haemoglobin and red cell enzyme changes in juvenile myeloid leukaemia. Br Med J, 1968; 1: 679-81.
18. Maurer, H. S., Vida, L. N., & Honig, G. R. Similarities of the erythrocytesinjuvenilechronicmyelogenousleukemiatofetal erythrocytes. Blood, 1972; 39: 778-84.
19. Humbert, J. R., Hathaway, W. E., Robinson, A., et al. Preleukemia in children with a missing bone marrow C chromosome and a myeloproliferative disorder. Br J Haematol, 1971; 21: 705-16.
20. Macdougall, L. G., Brown, J. A., Cohen, M. M., et al. C-monosomy myeloproliferative syndrome: a case of 7-monosomy. J Pediatr, 1974; 84: 256-9.
21. Sieff, C. A., Chessells, J. M., Harvey, B. A. M., et al. Monosomy 7 in childhood: a myeloproliferative disorder. Br J Haematol, 1981; 49: 235-49.
22. Evans, J. P., Czepulkowski, B., Gibbons, B., et al. Childhood monosomy 7 revisited. Br J Haematol, 1988; 69: 41-5.
23. Passmore, S. J., Hann, I. M., Stiller, C. A., et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood, 1995; 85: 1742-50.
24. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982; 51: 189-99.
25. Niemeyer, C. M., Aricò, M., Basso, G., et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood, 1997; 89: 3534-43.
26. Hasle, H. & Kerndrup, G. Atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia in children. Br J Haematol, 1995; 89: 428-9.
27. Niemeyer, C. M., Fenu, S., Hasle, H., et al. Differentiating juvenile myelomonocytic leukemia from infectious disease [letter]. Blood, 1998; 91: 365-7.
28. Hasle, H., Niemeyer, C. M., Chessells, J. M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 2003; 17: 277-82.
29. Passmore, J., Chessells, J., Kempski, H., et al. Paediatric MDS and JMML in the UK: a population-based study of incidence and survival. Br J Haematol, 2003; 121: 758-67.
30. Mark, Z., Toren, A., Amariglio, N., et al. Rearrangement of the immunoglobulinheavychaingenein juvenilechronicmyeloid leukaemia. Br J Haematol, 1995; 90: 353-7.
31. Holton, C. P. & Johnson, W.W. Chronic myelocytic leukemia in infant siblings. J Pediatr, 1968; 72: 377-83.
32. Bader, J. L. & Miller, R. W. Neurofibromatosis and childhood leukemia. J Pediatr, 1978; 92: 925-9.
33. Mays, J. A., Neerhout, T. C., Bagby, G. C., et al. Juvenile chronic granulocytic leukemia. Am J Dis Child, 1980; 134: 654-8.
34. Clark, R. D. & Hutter, J. J. Familial neurofibromatosis and juvenile chronicmyelogenous leukemia. Hum Genet, 1982; 60: 230-2.
35. Stiller, C. A., Chessells, J. M., & Fitchett, M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer, 1994; 70: 969-72.
36. Side, L. E., Emanuel, P. D., Taylor, B., et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood, 1998; 92: 267-72.
37. Watanabe, I., Horiuchi, T., Hatta, N., et al. Analysis of neurofibromatosis type 1 gene mutation in juvenile chronicmyelogenous leukemia. Acta Haematol, 1998; 100: 22-5.
38. Shannon, K. M., Watterson, P., Johnson, P., et al. Monosomy 7 myeloproliferativediseasein childrenwithneurofibromatosis, type 1: epidemiology and molecular analysis. Blood, 1992; 79: 1311-18.
39. Lutz, P., Zix-Kieffer, I., Souillet, G., et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC childrens leukemia cooperative group (CLCG). Bone Marrow Transplant, 1996; 18: 1111-16.
40. Bader-Meunier, B., Tchernia, G., Mielot, F., et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr, 1997; 130: 885-9.
41. Fukuda, M., Horibe, K., Miyajima, Y., et al. Spontaneous remission of juvenile chronicmyelomonocytic leukemia inaninfant with Noonan syndrome. J Pediatr Hematol Oncol, 1997; 19: 177-9.
42. Choong, K., Freedman, M. H., Chitayat, D., et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol, 1999; 21: 523-7.
43. Tartaglia, M., Niemeyer, C. M., Song, X., et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet, 2003; 34: 148-50.
44. Sasaki, H., Manabe, A., Kojima, S., et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia, 2001; 15: 1713-20.
45. Side, L. E. & Shannon, K. M. Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled. J Pediatr, 1997; 130: 857-9.
46. Tartaglia, M., Mehler, E. L., Goldberg, R., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet, 2001; 29: 465-8.
47. Luna-Fineman, S., Shannon, K. M., Atwater, S. K., et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood, 1999; 93: 459-66.
48. Sires, U. I., Mallory, S. B., Hess, J. L., et al. Cutaneous presentation of juvenile chronic myelogenous leukemia: a diagnostic and therapeutic dilemma. Pediatr Dermatol, 1995; 12: 364-8.
49. Anzai, H., Kikuchi, A., Kinoshita, A., et al. Recurrent annular erythema in juvenile chronic myelogenous leukaemia. Br J Dermatol, 1998; 138: 1058-60.
50. Heskel, N. S., White, C. R., Fryberger, S., et al. Aleukemic leukemia cutis: juvenile chronic granulocytic leukemia presenting with figurate cutaneous lesions. J Am Acad Dermatol, 1983; 9: 423-7.
51. Buescher, L. & Anderson, P. C. Circinate plaques heralding juvenile chronic myelogenous leukemia. Pediatr Dermatol, 1990; 7: 122-5.
52. Krilov, L. R., Jacobson, M., & Shende, A. Acute febrile neutrophilic dermatosis (Sweet's syndrome) presenting as facial cellulitis in a child with juvenile chronic myelogenous leukemia. Pediatr Infect Dis, 1987; 6: 77-9.
53. Jang, K. A., Choi, J. H., Sung, K. J., et al. Juvenile chronic myelogenous leukemia, neurofibromatosis 1, and xanthoma. J Dermatol, 1999; 26: 33-5.
54. Shaw, N. J. & Eden, O. B. Juvenile chronic myelogenous leukemia and neurofibromatosis in infancy presenting as ocular hemorrhage. Pediatr Hematol Oncol, 1989; 6: 23-6.
55. Nambu, M., Shimizu, K., Ito, S., et al. A case of juvenile myelomonocytic leukemia with ocular infiltration. Ann Hematol, 1999; 78: 568-70.
56. Hasle, H., Arico, M., Basso, G., et al.Myelodysplastic syndrome and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia, 1999; 13: 376-85.
57. Kitahara, M., Koike, K., Kurokawa, Y., et al. Lupus nephritis in juvenile myelomonocytic leukemia. Clin Nephrol, 1999; 51: 314-18.
58. Honig, G. R., Suarez, C. R., Vida, L. N., et al. Juvenile myelomonocytic leukemia (JMML)with the hematologic phenotype of severe beta thalassemia. Am J Hematol, 1998; 58: 67-71.
59. Shannon, K., Nunez, G., Dow, L. W., et al. Juvenile chronic myelogenous leukemia: surface antigen phenotyping bymonoclonal antibodies and cytogenetic studies. Pediatrics, 1986; 77: 330-5.
60. Kraus, M.D., Bartlett, N.L., Fleming, M.D., et al.Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Am J Surg Pathol, 1998; 22: 1255-66.
61. Ng, C. S., Lam, T. K., Chan, J. K., et al. Juvenile chronic myeloid leukemia. A malignancy of S-100 protein-positive histiocytes. Am J Clin Pathol, 1988; 90: 575-82.
62. Hess, J. L., Zutter, M.M., Castleberry, R.P., et al. Juvenile chronic myelogenous leukemia. Am J Clin Pathol, 1996; 105: 238-48.
63. Dover, G. J., Boyer, S. H., Zinkham, W. H., et al. Changing erythrocyte populations in juvenile chronicmyelocytic leukemia: evidence for disordered regulation. Blood, 1977; 49: 355-65.
64. Weatherall, D. J., Clegg, J. B., Wood, W. G., et al. Foetal erythropoiesis in human leukaemia. Nature, 1975; 257: 710-2.
65. Weinberg, R. S., Leibowitz, D., Weinblatt, D., et al. Juvenile chronic myelogenous leukaemia: the only example of truly fetal (not fetal-like) erythropoiesis. Br J Haematol, 1990; 76: 30-7.
66. Papayannopoulou, T., Nakamoto, B., Anagnou, N. P., et al. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood, 1991; 77: 2569-76.
67. Cannat, A. & Seligmann, M. Immunological abnormalities in juvenile myelomonocytic leukemia. Br Med J, 1973; 1: 71-4.
68. Butcher, M., Frenck, R., Emperor, J., et al.Molecular evidence thatchildhoodmonosomy7syndromeis distinct fromjuvenile chronic myelogenous leukemia and other childhood myeloproliferative disorders. Genes Chromosomes Cancer, 1995; 12: 50-7.
69. Michalova, K., Bartsch, O., Stary, J., et al. Partial trisomy of 3q detected by chromosomepainting in a case of juvenile chronic myelomonocytic leukemia. Cancer Genet Cytogenet, 1993; 71: 67-70.
70. Tosi, S., Mosna, G., Cazzaniga, G., et al.Unbalanced t(3;12) in a case of juvenile myelomonocytic leukemia (JMML) results in partial trisomy of 3q as defined by FISH. Leukemia, 1997; 11: 1465-8.
71. Borkhardt, A., Bojesen, S., Haas, O. A., et al. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci U S A, 2000; 97: 9168-73.
72. Amenomori, T., Tomonaga, M., Yoshida, Y., et al. Cytogenetic evidence for partially committed myeloid progenitor cell origin of chronic myelomonocytic leukaemia and juvenile chronic myeloid leukaemia: both granulocyte-macrophage precursors and erythroid precursors carry identical marker cells. Br J Haematol, 1986; 64: 539-46.
73. Inoue, S., Shibata, T., Ravindranath, Y., et al. Clonal origin of erythroid cells in juvenile chronic myelogenous leukemia. Blood, 1987; 69: 975-6.
74. Flotho, C., Valcamonica, S., Mach-Pascula, S., et al. Rasmutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia, 1999; 13: 32-7.
75. Busque, L., Gilliland, D. G., Prchal, J. T., et al. Clonality in juvenile chronic myelogenous leukemia. Blood, 1995; 85: 21-30.
76. Lau, R. C., Squire, J., Brisson, L., et al. Lymphoid blast crisis of B-lineage phenotype with monosomy 7 in a patient with juvenile chronic myelogenous leukemia (JCML). Leukemia, 1994; 8: 903-8.
77. Attias, D., Grunberger, T., Vanek, W., et al. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts. Leukemia, 1995; 9: 884-8.
78. Yamamoto, M., Nakagawa, M., Ichimura, N., et al. Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. Am J Hematol, 1996; 52: 212-14.
79. Nakazawa, T., Koike, K., Agematsu, K., et al. Cytogenetic clonality analysis in monosomy 7 associated with juvenile myelomonocytic leukemia: clonality in B and NK cells, but not in T cells. Leuk Res, 1998; 22: 887-92.
80. Miles, D. K., Freedman, M. H., Stephens, K., et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant disorders. Blood, 1996; 88: 4314-20.
81. Neubauer, A., Greenberg, P., Negrin, R., et al. Mutations in the ras proto-oncogenes in patients withmyelodysplastic syndromes. Leukemia, 1994; 8: 638-41.
82. Cooper, L. J., Shannon, K. M., Loken, M. R., et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 2000; 96: 2310-3.
83. Kirby, M. A., Weitzman, S., & Freedman, M. H. Juvenile chronic myelogenous leukemia: differentiation from infantile cytomegalovirus infection. Am J Pediatr Hematol Oncol, 1990; 12: 292-6.
84. Herrod, H. G., Dow, L. W., & Sullivan, J. L. Persistent Epstein-Barr virus infection mimicking juvenile chronic myelogenous leukemia: immunologic and hematologic studies. Blood, 1983; 61: 1098-104.
85. Lorenzana, A., Lyons, H., Sawaf, H., et al. Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. J Pediatr Hematol Oncol, 2002; 24: 136-41.
86. Yetgin, S., Cetin, M., Yenicesu, I., et al. Acute parvovirus B19 infection mimicking juvenile myelomonocytic leukemia. Eur J Haematol, 2000; 65: 276-8.
87. Kuijpers, T. W., Lier, R. A. van, Hamann, D., et al. Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest, 1997; 100: 1725-33.
88. Altman, A. J., Palmer, C. G., & Baehner, R. L. Juvenile "chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colonyforming cells. Blood, 1974; 43: 341-50.
89. Barak, Y., Levin, S., & Vogel, R. Juvenile and adult types of chronic granulocytic leukemia of childhood: growth patterns andcharacteristics of granulocytemacrophagecolonyforming cells. Am J Hematol, 1981; 10: 269-75.
90. Suda, T., Miura, Y., Mizoguchi, H., et al. Characterization of hemopoietic precursor cells in juvenile-type chronic myelocytic leukemia. Leuk Res, 1982; 6: 43-53.
91. Estrov, Z., Grunberger, T., Chan, H. S. L., et al. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood, 1986; 67: 1382-7.
92. Bagby, G. C, Jr., Dinarello, C. A., Neerhout, R. C., et al. Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. J Clin Invest, 1988; 82: 1430-6.
93. Gualtieri, R. J., Emanuel, P. D., Zuckermann, K. S., et al. Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood, 1989; 74: 2360-7.
94. Freedman, M. H., Cohen, A., Grunberger, T., et al. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol, 1992; 80: 40-8.
95. Emanuel, P. D., Bates, L. J., Zhu, S. W., et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol, 1991; 19: 1017-24.
96. Freedman, M. H., Hitzler, J. K., Bunin, N., et al. Juvenile chronic myelogenous leukemia multilineage CD34+ cells: aberrant growth and differentiation properties. Stem Cells, 1996; 14: 690-701.
97. Schiro, R., Longoni, D., Rossi, V., et al. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood, 1994; 83: 460-5.
98. Gualtieri, R. J., Castleberry, R. P., Gibbons, J., et al. Cell culture studies and oncogene expressions in juvenile chronic myelogenous leukemia. Exp Hematol, 1988; 16: 613-19.
99. Emanuel, P. D., Bates, L. J., Castleberry, R. P., et al. Selective hypersensitivity to granulocyte-macrophage colonystimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood, 1991; 77: 925-9.
100. Lapidot, T., Grunberger, T., Vormoor, J., et al. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary mice. Blood, 1996; 88: 2655-64.
101. Emanuel, P. D., Shannon, K. M., & Castleberry, R. P. Juvenilemyelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today, 1996; 2: 468-75.
102. Frankel, A. E., Lilly, M., Kreitman, R., et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemiaandchronicmyelomonocytic leukemia. Blood, 1998; 92: 4279-86.
103. Iversen, P.O., Rodwell, R. L., Pitcher, L., et al. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colonystimulating factor analogue E21R. Blood, 1996; 88: 2634-9.
104. Iversen, P. O., Lewis, I. D., Turczynowicz, S., et al. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenilemyelomonocytic leukemia in engrafted immunodeficient mice. Blood, 1997; 90: 4910-7.
105. Iversen, P.O., Hart, P. H., Bonder, C. S., et al. Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. Cancer Res, 1997; 57: 476-80.
106. Iversen, P. O. & Sioud, M. Modulation of granulocytemacrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. Blood, 1998; 92: 4263-8.
107. Kochetkova, M., Iversen, P. O., Lopez, A. F., et al. Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells. J Clin Invest, 1997; 99: 3000-8.
108. Emanuel, P. D., Zuckerman, K. S., Wimmer, R., et al. In vivo 13-cis retinoic acid therapy decreases the in vitro GM-CSF hypersensitivity in juvenile chronic myelogenous leukemia (JCML)[abstract]. Blood, 1991; 78(Suppl.1): 170a.
109. Castleberry, R. P., Emanuel, P. D., Zuckerman, K. S., et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. NEngl J Med, 1994; 331: 1680-4.
110. Cambier, N., Menot, M. L., Schlageter, M. H., et al. All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronicmyelomonocytic leukaemia. Hematol J, 2001; 2: 97-102.
111. Muccio, D. D., Brouillette, W. J., Breitman, T. R., et al. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem, 1998; 41: 1679-87.
112. Emanuel, P. D., Sokol, J. M., & Castleberry, R. P. Characterization of early response gene expression in juvenilemyelomonocyitc leukemia syndrome (JMML)[abstract]. Blood, 1995; 86(Suppl. 1): 728a.
113. Estrov, Z., Lau, A. S., Williams, B. R., et al. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. Exp Hematol, 1987; 15: 127-32.
114. Emanuel, P. D., Snyder, R. C., Wiley, T., et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood, 2000; 95: 639-45.
115. Sawai, N., Koike, K., Ito, S., et al. Aberrant growth of granulocyte-macrophage progenitors in juvenile chronic myelogenous leukemia in serum-free culture. Exp Hematol, 1996; 24: 116-22.
116. Zhang, Y. Y., Vik, T. A., Ryder, J. W., et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med, 1998; 187: 1893-902.
117. Sawai, N., Koike, K., Higuchi, T., et al. Thrombopoietin enhances the production ofmyeloid cells, but not megakaryocytes, in juvenile chronic myelogenous leukemia. Blood, 1998; 91: 4065-73.
118. Symann, M., de Montpellier, C., Ninane, J., et al."Spontaneous" erythroid progenitor cells in the circulation and monosomy 7 in juvenile chronic myelogenous leukemia. Cancer Genet Cytogenet, 1982; 6: 183-5.
119. Freeburn, R. W., Gale, R. E., Wagner, H. M., et al. Analysis of the coding sequence for the GM-CSF receptor alpha and beta chains in patients with juvenile chronicmyeloid leukemia (JCML). Exp Hematol, 1997; 25: 306-11.
120. Miyauchi, J., Asada, M., Sasaki, M., et al.Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood, 1994; 83: 2248-54.
121. Kalra, R., Paderanga, D. C., Olson, K., et al. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood, 1994; 84: 3435-9.
122. Sheng, X. M., Kawamura, M., Ohnishi, H., et al.Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leuk Res, 1997; 21: 697-701.
123. Bollag, G., Clapp, D. W., Shih, S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet, 1996; 12: 144-8.
124. Shannon, K. M., O'Connell, P., Martin, G., et al. Loss of the normal NF1 allele fromthe bone marrowof children with type 1 neurofibromatosis and malignant disorders. N Engl J Med, 1994; 330: 597-601.
125. Kai, S., Sumita, H., Fujioka, K., et al. Loss of heterozygosity of NF1 gene in juvenile chronic myelogenous leukemia with neurofibromatosis type 1. Int J Hematol, 1998; 68: 53-60.
126. Jacks, T., Shih, T. S., Schmitt, E. M., et al. Tumor predisposition in mice heterozygous for a targeted mutation in NF1. Nat Genet, 1994; 7: 353-61.
127. Largaespada, D. A., Brannan, C. I., Jenkins, N. A., et al. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet, 1996; 12: 137-43.
128. Birnbaum, R. A., O'Marcaigh, A., Wardak, Z., et al. Nf1 and GMCSF interact in myeloid leukemogenesis. Mol Cell, 2000; 5: 189-95.
129. Ingram, D. A., Wenning, M. J., Shannon, K., et al. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood, 2003; 101: 1984-6.
130. Tartaglia, M., Kalidas, K., Shaw, A., et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotypephenotype correlation, and phenotypic heterogeneity. Am J Hum Genet, 2002; 70: 1555-63.
131. Qu, C. K. Role of the SHP-2 tyrosine phosphatase in cytokineinduced signaling and cellular response. Biochim Biophys Acta, 2002; 1592: 297-301.
132. Qu, C. K., Nguyen, S., Chen, J., et al.Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood, 2001; 97: 911-14.
133. Hof, P., Pluskey, S., Dhe-Paganon, S., et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998; 92: 441-50.
134. Loh, M. L., Vattikuti, S., Schubbert, S. et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004; 103: 2325-31.
135. Ferraris, S., Lanza, C., Barisone, E., et al. Transient abnormal myelopoiesis in Noonan syndrome. J Pediatr Hematol Oncol, 2002; 24: 763-4.
136. Niemeyer, C. M., Tartaglia, M., Büchner, J., et al. Clinical characteristic of children with juvenile myelomonocytic leukemia (JMML)andgermlineofsomaticPTPN11mutations, rasmutations or neurofibromatosis type 1[abstract]. Blood, 2002; 100: 796a.
137. Yar, A., Laffargue, M., Mayeux, P., et al. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem, 2001; 276: 8856-64.
138. Cai, T., Nishida, K., Hirano, T., et al. Gab1 and SHP-2 promote Ras/MAPKregulation of epidermalgrowthanddifferentiation. J Cell Biol, 2002; 159: 103-12.
139. Itoh, T., Liu, R., Arai, K., et al. Differential influence of tyrosine residues of the common receptor beta subunit on multiple signals induced by human GM-CSF. J Allergy Clin Immunol, 1999; 103: S462-70.
140. Iversen, P. O., Turczynowicz, S., Lewis, J., et al. A second generation GM-CSF analogue that prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood, 1997; 90: 4910-7.
141. Bernard, F., Thomas, C., Emile, J.F., et al. Transienthematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood, 2002; 99: 2615-16.
142. Mahgoub, N., Taylor, B. R., Gratiot, M., et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood, 1999; 94: 2469-76.
143. Iversen, P. O., Emanuel, P. D., & Sioud, M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood, 2002; 99: 4147-53.
144. Donovan, S., See, W., Bonifas, J., et al. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell, 2002; 2: 507-14.
145. Blaydes, S. M., Kogan, S. C., Truong, B. T., et al. Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acutemyeloid leukemia. J Virol, 2001; 75: 9427-34.
146. Gerhardt, T. M., Schmahl, G. E., Flotho, C., et al. Expression of the EVI-1geneinhaematopoieticcells of childrenwithjuvenile myelomonocytic leukaemia and normal donors. Br J Haematol, 1997; 99: 882-7.
147. Privitera, E., Longoni, D., Brambillasca, F., et al. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML). Leukemia, 1997; 11: 2045-8.
148. Luria, D., Avigad, S., Cohen, I. J., et al. p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type 1. Cancer, 1997; 80: 2013-18.
149. Miyauchi, J., Asada, M., Tsunematsu, Y., et al. Abnormalities of the p53 gene in juvenile myelomonocytic leukaemia. Br J Haematol, 1999; 106: 980-6.
150. Xu, F., Taki, T., Yang, H. W., et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia aswell as acutemyeloidleukaemiabutnotinmyelodysplasticsyndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol, 1999; 105: 155-62.
151. Lilleyman, J. S., Harrison, J. F., &Black, J. A. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneus cytarabine and oral mercaptopurine. Blood, 1977; 49: 559-62.
152. Laver, J., Kushner, B. H., Steinherz, P. G. Juvenile chronic myeloid leukemia: therapeutic insights. Leukemia, 1987; 1: 730-3.
153. Hicsonmez, G., Cetin, M., Tunc, B., et al. Dramatic resolution of pleural effusion in children with chronic myelomonocytic leukemia following short-course high-dose methylprednisolone. Leuk Lymphoma, 1998; 29: 617-23.
154. Chan, H. S., Estrov, Z., Weitzman, S. S., et al. The value of intensive combinationchemotherapy for juvenile chronicmyelogenous leukemia. J Clin Oncol, 1987; 5: 1960-7.
155. De Heredia, C. D., Ortega, J. J., Coll, M. T., et al. Results of intensive chemotherapy in children with juvenile chronic myelomonocytic leukemia: A pilot study. Med Pediatr Oncol, 1998; 31: 516-20.
156. Woods, W. G., Barnard, D. R., Alonzo, T. A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol, 2002; 20: 434-40.
157. Festa, R. S., Shende, A., & Lanzkowsky, P. Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy. Med Pediatr Oncol, 1990; 18: 311-16.
158. Hasle, H., Kerndrup, G., Yssing, M., et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia, 1996; 10: 1269-73.
159. Mutz, I.D.&Zoubek, A. Transient response to alpha-interferon in juvenile chronic myelomonocytic leukemia. Pediatr Hematol Oncol, 1988; 5: 71-5.
160. Suttorp, M., Rister, M., & Schmitz, N. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol, 1994; 22: 358-9.
161. Aricò, M., Nespoli, L., Caselli, D., et al. Juvenile chronicmyeloid leukaemia and alpha-interferon. Eur J Pediatr, 1989; 148: 379-80.
162. Mirro, J., Dow, L.W., Kalwinsky, D. K., et al. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia. Cancer Treat Rep, 1986; 70: 363-7.
163. Hazani, A., Barak, Y., Berant, M., et al. Congenital juvenile chronic myelogenous leukemia: therapeutical trial with interferon alpha-2. Med Pediatr Oncol, 1993; 21: 73-6.
164. Maybee, D., Dubowy, R., Krischer, J., et al. Unusual toxicity of high dose alpha interferon (aIFN) in the treatment of juvenile chronic myelogenous leukemia (JCML)[abstract]. Proc. Am. Soc. Clin. Oncol, 1992; 1: 950a.
165. Ohta, H., Kawai, M., Sawada, A., et al. Juvenilemyelomonocytic leukemia relapsing after allogeneic bone marrowtransplantation successfully treated with interferon-alpha. Bone Marrow Transplant, 2000; 26: 681-3.
166. Pui, C. H. & Aricò, M. Isotretinoin for juvenile chronic myelogenous leukemia. NEngl J Med, 1995; 332: 1520-1.
167. Castelberry, R. P., Chang, M., Maybee, D., et al. A phase II study of 13-cis retinoic acid in juvenile myelomonocytic leukemia [abstract]. Blood, 1997; 90: 346a.
168. Maguire, A. M., Vowels, M. R., Russell, S., et al. Allogeneic bone marrow transplant improves outcome for juvenile myelomonocytic leukaemia. J Paediatr Child Health, 2002; 38: 166-9.
169. Steinherz, P. G., Exelby, P. R., Young, J., et al. Splenectomy after angiographic embolization of the splenic artery in patients with massive splenomegaly and severe thrombocytopenia, in juvenile subacute myelomonocytic leukemia. Med Pediatr Oncol, 1984; 12: 28-32.
170. Locatelli, F., Niemeyer, C., Angelucci, E., et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol, 1997; 15: 566-73.
171. Bunin, N., Saunders, F., Leahey, A., et al. Alternative donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol, 1999; 21: 479-85.
172. Smith, F. O., King, R., Nelson, G., et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol, 2002; 116: 716-24.
173. Manabe, A., Okamura, J., Yumura-Yagi, K., et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMMLWorking Group. Leukemia, 2002; 16: 645-9.
174. Chown, S. R., Potter, M. N., Cornish, J., et al. Matched and mismatched unrelated donor bone marrow transplantation for juvenile chronic myeloid leukaemia. Br J Haematol, 1996; 93: 674-6.
175. Matthes-Martin, S., Mann, G., Peters, C., et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant, 2000; 26: 377-82.
176. Peltier, J. Y., Girault, D., Debré, M., et al. Donor for BMT with haemoglobin H disease. Bone Marrow Transplant, 1993; 12: 81-4.
177. Donadieu, J., Stephan, J. L., Blanche, S., et al. Treatment of juvenilechronicmyelomonocyticleukemiabyallogeneicbone marrow transplantation. Bone Marrow Transplant, 1994; 13: 777-82.
178. Wagner, J. E., Broxmeyer, H.E., Byrd, R. L., et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood, 1992; 79: 1874-81.
179. Mac Millan, M. L., Davies, S. M., Orchard, P. J., et al.Haemopoietic cell transplantation in children with juvenilemyelomonocytic leukaemia. Br J Haematol, 1998; 103: 552-8.
180. Ohnuma, K., Isoyama, K., Ikuta, K., et al. Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies. Br J Haematol, 2001; 112: 981-7.
181. Locatelli, F., Noellke, P., Zecca, M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOGMDS/EBMT trial. Blood, 2005; 105: 410-19.
182. Sanders, J. E., Buckner, C. D., Thomas, E. D., et al. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood, 1988; 71: 1144-6.
183. Urban, C., Schwinger, W., Slavc, I., et al. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia. Bone Marrow Transplant, 1990; 5: 353-6.
184. Rubie, H., Attal, M., Demur, C., et al. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes. Bone Marrow Transplant, 1994; 13: 759-62.
185. Rassam, S. M., Katz, F., Chessells, J. M., et al. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect? Bone Marrow Transplant, 1993; 11: 247-50.
186. Kressler, E. J., Haas, O. A., Konig, M., et al. Extramedullary relapse despite graft-versus-leukemia effect after bone marrow transplantation in a girl with juvenile myelomonocytic leukemia. Leuk Lymphoma, 1999; 33: 597-600.
187. Orchard, P. J., Miller, J. S., McGlennen, R., et al. Graftversus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant, 1998; 22: 201-3.
188. Pamphilon, D. H., Cornish, J. M., Goodman, S., et al. Successful second unrelated donor BMT in a child with juvenile chronic myeloid leukaemia: documentation of chimaerism using the polymerase chain reaction. Bone Marrow Transplant, 1993;11: 81-4.
189. Yoshimi, A., Locatelli, F., Trebo, M., et al. Treatment for patients relapsing with juvenile myelomonocytic leukemia after allogeneic stem cell transplantation: the EWOG-MDS study. Leuk Res, 2005(Suppl. 1); 516 [abstract].
190. Grier, H. E. & Civin, C. I. Myeloid leukemias, myelodysplasia and myeloproliferative disease in children. In D. G. Nathan & S. H. Orkin, eds., Hematology of Infancy and Childhood (Philadelphia, PA:W.B. Saunders, 1998), pp. 1300-8.
191. Hall, G. W. Cytogenetic and molecular genetic aspects of childhoodmyeloproliferative/myelodysplastic disorders. Acta Haematol, 2002; 108: 171-9.
192. Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukaemia. Science, 1960; 132: 1497.
193. Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature, 1973; 243: 290-3.
194. Kurzrock, R., Gutterman, J. U., & Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med, 1988; 319: 990-8.
195. Kurzrock, R., Kantarjian, H. M., Druker, B. J., et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med, 2003; 138: 819-30.
196. Deininger, M. W., Goldman, J. M., & Melo, J. V. The molecular biology of chronicmyeloid leukemia. Blood, 2000; 96: 3343-56.
197. Groffen, J., Stephenson, J. R., Heisterkamp, N., et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 1984; 36: 93-9.
198. Heisterkamp, N., Stam, K., Groffen, J., et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature, 1985; 315: 758-61.
199. Biernaux, C., Loos, M., Sels, A., et al. Detection of major bcrabl gene expression at a very low level in blood cells of some healthy individuals. Blood, 1995; 86: 3118-22.
200. Kurzrock, R., Bueso-Ramos, C. E., Kantarjian, H., et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol, 2001; 19: 2915-26.
201. Sawyers, C. L. Chronic myeloid leukemia. N Engl J Med, 1999; 340: 1330-40.
202. Kurzrock, R., Kantarjian, H. M., Shtalrid, M., et al. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood, 1990; 75: 445-52.
203. Emanuel, P. D. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol, 1999; 105: 852-63.
204. Sokal, J. E., Cox, E. B., Baccarani, M., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 1984; 63: 789-99.
205. Hasford, J., Pfirrmann, M., Hehlmann, R., et al. for the Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst, 1998; 90: 850-8.
206. Chronic Myeloid Leukemia Trialists, Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst, 1997; 89: 1616-20.
207. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. NEngl J Med, 1994; 330: 820-5.
208. Hehlmann, R., Heimpel, H., Hasford, J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 1994; 84: 4064-77.
209. Allan, N. C., Richards, S. M., & Shepherd, P. C. UK Medical Research Council randomised, multicentre trial of interferonalpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response.The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet, 1995; 345: 1392-7.
210. Baranger, L., Baruchel, A., Leverger, G., et al. Monosomy-7 in childhood hemopoietic disorder. Leukemia, 1990; 4: 345-9.
211. Guilhot, F., Chastang, C., Michallet, M., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. NEngl J Med, 1997; 337: 223-9.
212. Baccarani, M., Rosti, G., de Vivo, A., et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronicmyeloid leukemia. Blood, 2002; 99: 1527-35.
213. Druker, B. J., Tamura, S., Buchdunger, E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996; 2: 561-6.
214. Druker, B. J. & Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 2000; 105: 3-7.
215. Druker, B. J.&Talpaz, M., Resta, D. J., et al.Efficacyandsafety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEngl J Med, 2001; 344: 1031-7.
216. Kantarjian, H., Sawyers, C., Hochhaus, A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. NEngl J Med, 2002; 346: 645-52.
217. Talpaz, M., Silver, R. T., Druker, B. J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002; 99: 1928-37.
218. Sawyers, C. L., Hochhaus, A., Feldman, E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002; 99: 3530-9.
219. Kantarjian, H. M., Cortes, J., O'Brien, S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 2002; 99: 3547-53.
220. O'Brien, S. G., Guilhot, F., & Larson, R. A. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukaemia. N Engl J Med, 2003; 348: 994-1004.
221. Weisberg, E. & Griffin, J. D. Mechanism of resistance to the ABLtyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 2000; 95: 3498-505.
222. Gorre, M. E., Mohammed, M., Ellwood, K., et al. Clinical resistanceto STI-571 cancer therapy caused by BCR-ABLgenemutation or amplification. Science, 2001; 293: 876-80.
223. Bhatia, R., Holtz, M., Niu, N., et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 2003; 101: 4701-7.
224. Goldman, J. M., Szydlo, R., Horowitz, M. M., et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood, 1993; 82: 2235-8.
225. Rhee, F. van, Szydlo, R. M., Hermans, J., et al. Long-termresults after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 1997; 20: 553-60.
226. Goldman, J. M., Apperley, J. F., Jones, L., et al. Bone marrow transplantation for patients with chronic myeloid leukemia. NEngl J Med, 1986; 314: 202-7.
227. Hansen, J. A., Gooley, T. A., Martin, P. J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. NEngl J Med, 1998; 338: 962-8.
228. McGlave, P. B., Shu, X. O., Wen, W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood, 2000; 95: 2219-25.
229. Davies, S. M., De For, T. E., McGlave, P. B., et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med, 2001; 110: 339-46.
230. Gratwohl, A., Hermans, J., Goldman, J. M., et al. Risk assessment for patients with chronicmyeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 1998; 352: 1087-92.
231. Gamis, A. S., Haake, R., McGlave, P., et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosomepositive chronic myelogenous leukemia in children. J Clin Oncol, 1993; 11: 834-8.
232. Dini, G., Rondelli, R., Miano, M., et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosomepositive chronic myelogenous leukemia in children: experience of eight european countries. The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant, 1996; 18(Suppl. 2): 80-5.
233. Cwynarski, K., Roberts, I. A., Iacobelli, S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood, 2003; 102: 1224-31.
234. Sasazuki, T., Juji, T., Morishima, Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. NEngl J Med, 1998; 339: 1177-85.
235. Petersdorf, E. W., Gooley, T. A., Anasetti, C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 1998; 92: 3515-20.
236. Kolb, H. J., Mittermuller, J., Clemm, C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrowtransplant patients. Blood, 1990; 76: 2462-5.
237. Collins, R. H, Jr., Shpilberg, O., Drobyski, W. R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol, 1997; 15: 433-44.
238. Kolb, H. J., Schattenberg, A., Goldman, J. M., et al.Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 1995; 86: 2041-50.
239. Locatelli, F. The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation. Br J Haematol, 1998; 102: 633-8.
240. Adamson, J. W., Fialkow, P. J., Murphy, S., et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med, 1976; 295: 913-16.
241. Berlin, N. I. Diagnosis and classification of the polycythemias. Semin Hematol, 1975; 12: 339-51.
242. Pearson, T. C. &Messinezy, M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma, 1996; 22(Suppl. 1): 87-93.
243. Pierre, R., Imbert, M., Thiele, J., et al. Polycythemia vera. In E. S., Jaffe, N. L., Harris, H., Stein, &J.W. Vardiman, eds., World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoitic and Lymphoid Tissues. (Lyon, France: IARC, 2001), pp. 32-4.
244. Kralovics, R., Passamonti, F., Buser, A. S., et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005; 352: 1779-90.
245. Goerttler, P. S., Steimle, C., Marz, E., et al. The Jak2V617F mutation, PRV-1 overexpression and EECformation define a similar cohort of MPD patients. Blood, 2005; Jun 28 [Epub ahead of print].
246. Frezzato, M., Ruggeri, M., Castaman, G., et al. Polycythemia vera and essential thrombocythemia in young patients. Haematologica, 1993; 78(Suppl. 2): 11-17.
247. Testa, J. R., Kanofsky, J. R., Rowley, J. D., et al. Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol, 1981; 11: 29-45.
248. Solberg, L. A, Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol, 2002; 29(Suppl. 10): 10-5.
249. Nand, S., Stock, W., Godwin, J., et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol, 1996; 52: 42-6.
250. Prchal, J.T.&Sokol, L. "Benign erythrocytosis"andother familial and congenital polycythemias. Eur J Haematol, 1996; 57: 263-8.
251. Kralovics, R. & Prchal, J. T. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol, 2001; 68: 115-21.
252. Juvonen, E., Ikkala, E., Fyhrquist, F., et al. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood, 1991; 78: 3066-9.
253. de la, Chapelle, A., Traskelin, A. L., & Juvonen, E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A, 1993; 90: 4495-9.
254. Hasle, H. Incidence of essential thrombocythaemia in children. Br J Haematol, 2000; 110: 751.
255. Taksin, A. L., Couedic, J. P., Dusanter-Fourt, I., et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathicmyelofibrosis is not related to a c-mpl mutation or to an autocrine stimulationby Mpl-L. Blood, 1999; 93: 125-39.
256. Dror, Y. & Blanchette, V. S. Essential thrombocythaemia in children. Br J Haematol, 1999; 107: 691-8.
257. Murphy, S., Iland, H., Rosenthal, D., et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol, 1986; 23: 177-82.
258. Cortelazzo, S., Finazzi, G., Ruggeri, M., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. NEngl J Med, 1995; 332: 1132-6.
259. Harrison, C. N., Campbell, P. J., Buck, G., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEngl J Med, 2005; 353: 33-45.
260. Kondo, T., Okabe, M., Sanada, M., et al. Familial essential thrombocythemia associated with one-base deletion in the 5_-untranslated region of the thrombopoietin gene. Blood, 1998; 92: 1091-6.
261. Wiestner, A., Padosch, S. A., Ghilardi, N., et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol, 2000; 110: 104-9.
262. Tefferi, A. Myelofibrosiswithmyeloid metaplasia. N Engl J Med, 2000; 342: 1255-65.
263. Boxer, L. A., Camitta, B. M., Berenberg, W., et al.Myelofibrosismyeloid metaplasia in childhood. Pediatrics, 1975; 55: 861-5.
264. Altura, R. A., Head, D. R., & Wang, W. C. Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol, 2000; 109: 459-62.
265. Sekhar, M., Prentice, H. G., Popat, U., et al. Idiopathic myelofibrosis in children. Br J Haematol, 1996; 93: 394-7.
266. Dewald, G. W. & Wright, P. I. Chromosome abnormalities in the myeloproliferative disorders. Semin Oncol, 1995; 22: 341-54.
267. Varki, A., Lottenberg, R., Griffith, R., et al.Thesyndromeof idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore), 1983; 62: 353-71.
268. Barosi, G., Berzuini, C., Liberato, L. N., et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol, 1988; 70: 397-401.
269. Dupriez, B., Morel, P., Demory, J. L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 1996; 88: 1013-18.
270. Tefferi, A., Elliot, M. A., Yoon, S. Y., et al. Clinical and bone marroweffects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood, 2001; 97: 1896.
271. Elliott, M. A., Mesa, R. A., Li, C. Y., et al. Thalidomide treatment inmyelofibrosis withmyeloid metaplasia. Br J Haematol, 2002; 117: 288-96.
272. Guardiola, P., Anderson, J. E., Bandini, G., et al. Allogeneic stem cell transplantation for agnogenicmyeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 1999; 93: 2831-8.
273. Anderson, J. E., Tefferi, A., Craig, F., et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood, 2001; 98: 586-93.
274. Brito-Babapulle, F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol, 2003; 121: 203-23.
275. Bain, B., Pierre, R., Imbert, M., et al. Chronic eosinophilic leukemia/hypereosinophilic syndrome. In E. S. Jaffe, N. L., Harris, H., Stein, & J. W. Vardiman, eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (Lyon, France: IARC, 2001), pp. 29-34.
276. Aoki, Y., Nata, M., Hashiyada, M., et al. Sudden unexpected death in childhood due to eosinophilicmyocarditis. Int J Legal Med, 1996; 108: 221-4.
277. Kumar, K. A., Anjaneyulu, A., &Murthy, J. M. Idiopathic hypereosinophilic syndrome presenting as childhood hemiplegia. Postgrad Med J, 1992; 68: 831-3.
278. Falade, A. G., Darbyshire, P. J., Raafat, F., et al. Hypereosinophilic syndrome in childhood appearing as inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 1991; 12: 276-9.
279. Horenstein, M. S., Humes, R., Epstein, M. L., et al. Loffler's endocarditis presenting in 2 children as fever with eosinophilia. Pediatrics, 2002; 110: 1014-18.
280. Rauch, A. E., Amyot, K.M., Dunn, H.G., et al.Hypereosinophilic syndrome and myocardial infarction in a 15-year-old. Pediatr Pathol Lab Med, 1997; 17: 469-86.
281. Schulman, H., Hertzog, L., Zirkin, H., et al.Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol, 1999; 29: 595-7.
282. Meeker, T. C., Hardy, D., Willman, C., et al. Activation of the interleukin-3geneby chromosometranslocation in acutelymphocytic leukemia with eosinophilia. Blood, 1990; 76: 285-9.
283. Hogan, M. B., Piktel, D., & Landreth, K. S. IL-5 production by bone marrow stromal cells: implications for eosinophilia associated with asthma. J Allergy Clin Immunol, 2000; 106: 329-36.
284. Darbyshire, P. J., Shortland, D., Swansbury, G. J., et al. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation. Br J Haematol, 1987; 66: 483-6.
285. Michel, G., Thuret, I., Capodano, A. M., et al. Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: response to corticotherapy. Med Pediatr Oncol, 1991; 19: 62-5.
286. Sakamoto, K., Erdreich-Epstein, A., de Clerck, Y., et al. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol, 1992; 14: 348-51.
287. Bakhshi, S., Hamre, M., Mohamed, A. N., et al. t(5;9)(q11;q34): anovel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol, 2003; 25: 82-4.
288. Jani, K., Kempski, H. M., & Reeves, B. R. A case ofmyelodysplasia with eosinophilia having a translocation t(5;12) (q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol, 1994; 87: 57-60.
289. Chusid, M. J., Dale, D. C., West, B. C., et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore), 1975; 54: 1-27.
290. Simon, H. U., Plotz, S. G., Dummer, R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. NEngl J Med, 1999; 341: 1112-20.
291. Markwell, H. S. & Wilson, E. Separation of hypereosinophilic syndrome from acute lymphoblastic leukemia with reactive eosinophilia. West J Med, 1983; 138: 269-70.
292. Cools, J., De Angelo, D. J., Gotlib, J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. NEngl J Med, 2003; 348: 1201-4.
293. Gleich, G. J., Leiferman, K. M., Pardanani, A., et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet, 2002; 359: 1577-8.
294. Valent, P., Akin, C., Sperr, W. R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol, 2003; 122: 695-717.
295. Hartmann, K. & Metcalfe, D. D. Pediatric mastocytosis. Hematol Oncol Clin North Am, 2000; 14: 625-40.
296. Metcalfe, D. D. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol, 1991; 96: 45-6S.
297. Valent, P., Akin, C., Sperr, W. R., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res, 2003; 27: 635-41.
298. Valent, P., Horny, H.-P., Li, C. Y., et al. Mastocytosis. In E. S. Jaffe, N. L., Harris, H., Stein, & J. W. Vardiman, eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumoursof Haematopoieticand Lymphoid Tissues. (Lyon, France: IARC, 2001), pp. 293-302.
299. Valent, P. 1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Eur J Clin Invest, 1995; 25: 715-20.
300. Orfao, A., Escribano, L., Villarrubia, J., et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. Am J Pathol, 1996; 149: 1493-9.
301. Longley, B. J., Tyrrell, L., Lu, S. Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet, 1996; 12: 312-14.
302. Ma, Y., Zeng, S., Metcalfe, D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 2002; 99: 1741-4.
303. Travis, W. D., Li, C. Y., Bergstralh, E. J., et al. Systemic mast cell disease. Analysis of 58 cases and literature review.Medicine (Baltimore), 1988; 67: 345-68.
304. Sperr, W. R., Jordan, J. H., Fiegl, M., et al. Serumtryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol, 2002; 128: 136-41.
305. Büttner, C., Henz, B. M., Welker, P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol, 1998; 111: 1227-31.
306. Longley, B. J, Jr., Metcalfe, D. D., Tharp, M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A, 1999; 96: 1609-14.
307. Azana, J. M., Torrelo, A., Mediero, I. G., et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol, 1994; 11: 102-6.
308. Vardiman, J.W., Brunning, R.D., &Harris, N. L. Chronicmyeloproliferative disorders. In E. S. Jaffe, N. L. Harris, H. Stein, & J. W. Vardiman, eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (Lyon, France: IARC, 2001), pp. 17-44.